Immunobiotic lactobacilli reduce viral-associated pulmonary damage through the modulation of inflammation–coagulation interactions
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The exacerbated disease due to immune- and coagulative-mediated pulmonary injury during acute respiratory viruses infection results in severe morbidity and mortality. Identifying novel approaches to modulate virus-induced inflammation-coagulation interactions could be important alternatives for treating acute respiratory viruses infections. In this study we investigated the effect of the probiotic strain Lactobacillus rhamnosus CRL1505 on lung TLR3-mediated inflammation, and its ability to modulate inflammation-coagulation interaction during respiratory viral infection. Our findings reveal for the first time that a probiotic bacterium is able to influence lung immune-coagulative reaction triggered by TLR3 activation, by modulating the production of proinflammatory and anti-inflammatory cytokines as well as expression of tissue factor and thrombomodulin in the lung. We also demonstrated that the preventive treatment with the probiotic bacteria beneficially modulates the fine tune balance between clearing respiratory viruses (respiratory syncytial virus and influenza virus) and controlling immune-coagulative responses in the lung, allowing normal lung function to be maintained in the face of a viral attack. Our data also pinpoint a crucial role for IL-10 in the immune protection induced by L. rhamnosus CRL1505 during respiratory viral infections. These observations might be helpful to propose new preventive or therapeutic approaches to better control virus-inflammatory lung damage using probiotic functional foods.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pulmonary pathology of severe acute respiratory syndrome in Toronto
Hwang, D. M., Chamberlain, D. W., Poutanen, S. M., Low, D. E., Asa, S. L., & Butany, J. (2005) · Modern Pathology · doi:10.1038/modpathol.3800247 · Cited by 332
Respiratory Syncytial Virus Activates Innate Immunity through Toll-Like Receptor 2
Murawski, M. R., Bowen, G. N., Cerny, A. M., Anderson, L. J., Haynes, L. M., Tripp, R. A., Kurt-Jones, E. A., & Finberg, R. W. (2009) · Journal of Virology · doi:10.1128/jvi.00671-08 · Cited by 279
Cited by
Microorganisms with Claimed Probiotic Properties: An Overview of Recent Literature
Fijan, S. (2014) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph110504745 · Cited by 1,059
“Lactobacillus rhamnosus CRL1505 has even been effective in reducing viral-associated pulmonary damage through controlling immune-coagulative responses and clearing respiratory viruses [37].”
BackgroundUpdate of probiotics in human world: A nonstop source of benefactions till the end of time
Zommiti, M., Feuilloley, M. G. J., & Connil, N. (2020) · Microorganisms · doi:10.3390/microorganisms8121907 · Cited by 225
Assessing the Risk of Probiotic Dietary Supplements in the Context of Antibiotic Resistance
Zheng, M., Zhang, R., Tian, X., Zhou, X., Pan, X., & Wong, A. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00908 · Cited by 218
“Other notable health claims include the prevention of mammary cancer (Lakritz et al., 2014), the reduction of viral-associated pulmonary damage (Zelaya et al., 2014) and the decrease in cholesterol level that reduces the risk of cardiovascular diseases (Ejtahed et al., 2011).”
Background
Metadata
- Authors
- Zelaya, H., Tsukida, K., Chiba, E., Marranzino, G., Alvarez, S., Kitazawa, H., Agüero, G., & Villena, J.
- Venue
- International Immunopharmacology
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 19
- Issue
- 1
- Pages
- 161-173
- ISSN
- 1567-5769 (ISSN-L)
- OpenAlex
- W2035671496
- Cited by
- 74
- References
- 2
- FWCI
- 8.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.